Released Aug 16, 2021, before the open
10-Q filed Aug 16, 2021, 47 days after period end · 0001558370-21-011752
Q2 2021 · 10-Q
Revenue$6.43M$6.43M −41.4% vs Q2 2020−43.2% vs Q1 2021
Net Income-$11.24M-$11.24M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.25-$0.25 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$9,166,000N/M
Operating Cash Flowderived$6,516,000N/M
Free Cash Flowderived$6,235,000N/M
Margins · derived
Operating margin-142.6%−122.2 pt vs Q2 2020
Net margin-174.9%−137.1 pt vs Q2 2020
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $6.43M | $10.97M | $12.25M | $2.01M |
| Net Income | -$11.24M | -$4.15M | -$7.74M | -$8.46M |
| EPS Diluted | -$0.25 | -$0.13 | -$0.52 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR